ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0815

Implementing Treat to Target (TTT) for Rheumatoid Arthritis (RA) Through a Virtual Learning Collaborative (LC) Program During COVID

DH Solomon1, Theodore Pincus2, Nancy Shadick1, Jacklyn Stratton1, Jack Ellrodt1, Leah Santacroce1, Jeffrey Katz1, Josef Smolen3, Prem Chatpar4, Breanna Mundell4, Mary Stocks4, Christina Downey5, Karina Torralba6, Douglas White7, Meggan Baudek7, Steven Szlembarski7, Sharon Barnhart7, Jawad Bilal8, Dylan Lee8, Albert Redford8, Julia Buchfuhrer9, Helene Kramer8, C. Kent Kwoh10, Michel Villatoro-Villar8, Asha Patnaik11, Edgardo Guzman11, Rebecca Trachtman12, John Tesser13, Dijana Music14, Lexi Mickey15, Mona Amin16, Jeffrey Potter17, Juan Schmukler18, Joshua Sundhar19, Jessica Sheingold20, Diane Horowitz21, Hannah Gulko21, Robert Quinet22, Swathi Dhulipala23, Ronak Patel24, Chandana Keshavamurthy25, Guiset Carvajal Bedoya26, Rhonda Dunn27, Bharat Kumar27, Aleksander Lenert27, Hanna Zembrzuska27 Matthew Gebre28, Petar Lenert29, Allen Anandarjah30, Annie Yang30, Linda Grinnell-Merrick30, Shadefai Goldsmith30, Jonna Zelie30, Leanna Wise31, Nicole Zagelbaum Ward32 and Jeffrey Kaine33 1Brigham and Women's Hospital, Boston, MA, 2Rush University Medical Center, Chicago, IL, 3University of Vienna, Vienna, Austria, 4Dr. Chatpar and Associates, LLC, Plainview, NY, 5Loma Linda University Medical Center, Redlands, CA, 6Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, 7Gundersen Health, La Crosse, WI, 8University of Arizona, Phoenix, AZ, 9University of Arizona, Pheonix, AZ, 10University of Arizona College of Medicine, Tuscon, AZ, 11Stony Brook School of Medicine, Stony Brook, NY, 12Icahn School of Medicine at Mount Sinai, New York, NY, 13Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, 14Arizona Arthritis and Rheumatology Associates, Glendale, AZ, 15Arthritis and Rheumatology Associates- Glendale, Glendale, AZ, 16Arthritis and Rheumatology Associates- Phoenix, Phoenix, AZ, 17Arthritis & Rheumatism Associates, Wheaton, MD, 18Mount Sinai- Chicago, Chicago, IL, 19Arthritis Rheum & Back Disease Assoc., Voorhees, NJ, 20MedStar Georgetown University Hospital, Washington, DC, 21Northwell Health, Great Neck, NY, 22Ochsner Health, River Ridge, LA, 23Ochsner Clinic Foundation, River Ridge, LA, 24Ochsner Health, Jefferson, LA, 25Ochsner, New Orleans, LA, 26University of Colorado, Aurora, CO, 27University of Iowa, Iowa City, IA, 28Loma Linda University Medical Center, Loma Linda, CA, 29University of Iowa Medical School, Iowa City, IA, 30University of Rochester, Rochester, NY, 31LAC+USC/Keck Medicine of USC, Pasadena, CA, 32LAC+USC Medical Center, Los Angeles, CA, 33Cullowhee, NC

Meeting: ACR Convergence 2021

Keywords: quality of care, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: TTT has been shown in multiple RCTs to be an effective paradigm for managing RA, however TTT has not been uniformly implemented in US rheumatology. In a prior RCT, we found improvement implementation of TTT at selected rheumatology practices during a face-to-face 9-month Learning Collaborative (LC) (1). An LC is a method for group-based quality improvement, which has been successfully used in healthcare. In the current study, we tested a 6-month virtual LC that took place during the COVID pandemic as a method for improving implementation and adherence with TTT in 18 rheumatology practices in the US.

Methods: During 2020-2021, we conducted a virtual LC for TTT in RA. All meetings used video-conferencing and a website allowed participants to share documents and data. The LC consisted of one 5-6 hour kickoff session and 6 monthly webinars. Faculty and participants discussed procedures for TTT, its rationale, and methods for quality improvement; we focused on Plan-Do-Study-Act (PDSA) cycles as a method for implementing TTT. Practices were asked to meet and carry-out PDSA cycles. Each monthly webinar discussed the PDSAs, reinforced topics from the kick-off, and demonstrated data on TTT adherence from the practices. Practices were asked to review 20-25 visit notes from RA patients and to input de-identified data into the website. The data were analyzed and shared in the monthly webinars. The webinars allowed sites to discuss the data and share best (and worst) practices. Adherence with TTT was measured as a percentage of the TTT component processes: 1) measure and document RA disease activity (any standard disease activity measure considered acceptable, e.g., CDAI, RAPID3, DAS28), 2) determine a target disease activity, 3) make treatment changes if not at target, and 4) document shared decision-making.

Results: 18 sites from 10 states (plus Washington DC) participated; they represented 45 rheumatology clinicians (MDs, nurse practitioners, and physician’s assistants) who attended the kick-off and/or monthly webinars. During the 6 months, sites entered data on 1826 patient visits. Adherence with TTT improved over the six months from a mean of 50.7% at baseline to 83.7% at study completion (see Figure 1, p for trend < 0.001). Each aspect of TTT measured also improved (see Figure 2). The main reason for TTT non-adherence was that clinicians changed treatment in only 59% of visits where patients were not at target. Some reasons documented (not mutually exclusive) for not intensifying treatment when patients were not at target are shown in Table 1. They include patient preference (33%), clinician preference (19%), clinician deemed symptoms were not from RA (25%), and the desire to observe the treatment effect for more time (19%).

Conclusion: Implementing TTT for RA can be improved through a relatively low-cost virtual LC. This improvement in TTT was observed despite the COVID pandemic. We would urge professional societies to experiment with implementing LC quality improvement programs virtually to facilitate wider dissemination of best practices.

1. Solomon, D. H., et al. Implementation of TTT in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. Arthritis Rheumatol 2017;69:1374-1380.


Disclosures: D. Solomon, Abbvie, 5, Amgen, 5, Genentech, 5; T. Pincus, Medical History Services LLC, 8, 9, 10, 12; N. Shadick, BMS, 5, Mallinckrodt, 5, Sanofi/Regeneron, 5, Crescendo Biosciences, 5; J. Stratton, None; J. Ellrodt, None; L. Santacroce, None; J. Katz, Samumed, 5; J. Smolen, Abbvie, 5, 6; P. Chatpar, None; B. Mundell, None; M. Stocks, None; C. Downey, None; K. Torralba, GlaxoSmithKline, 12, Clinical Trials Support, UCB, 2, Exagen, 2, Aurinia Pharmaceuticals, 2, Ultrasound School of North American Rheumatologists (SUSONAR) Southern California Rheumatology Society (SCRS), 4, Janssen, 12, Support for educational programs, Radius Health, 12, Support for educational programs, Amgen, 12, Support for educational programs, Novartis, 2, 12, Clinical Trials Support, Pfizer, 12, Support for educational programs, AstraZeneca, 12, Clinical Trials Support; D. White, None; M. Baudek, None; S. Szlembarski, None; S. Barnhart, None; J. Bilal, None; D. Lee, None; A. Redford, None; J. Buchfuhrer, None; H. Kramer, None; C. Kwoh, Lilly, 5, Abbvie, 5, Kolon Tissue Gene, 12, DSMB, Regeneron, 1, LG Chem, 1; M. Villatoro-Villar, None; A. Patnaik, None; E. Guzman, None; R. Trachtman, None; J. Tesser, Bristol-Myers Squibb, 1, 2, 5, 6, Janssen, 1, 2, 5, 6, Eli Lily, 1, 2, 5, 6, Pfizer, 1, 2, 5, 6, AbbVie, 1, 2, 5, 6, Astra Zeneca, 1, 2, 6, GlaxcoSmithKline, 6, Amgen, 5, 6, Boehringer Ingelheim, 5, Genentech, 5, Horizon Therapeutics plc, 5, SunPharma, 5, Gilead, 2, 5, Novartis, 2, 5, Celgene, 5, Merck KG, 5, Sandoz, 5, Setpoint, 5, UCB Pharma, 5, Crescendo Biosciences/Myriad, 6, Sanofi-Genzyme, 1, 2, 6, Aurinia, 1, 2, 6, Samumed/Biosplice, 1, 2, 5, Vorso, 5, Selecta, 5, Exagen, 5, CSL Behring, 5, Organogenesis, 5, D R L Pharma, 5, Emerald Health, 5; D. Music, None; L. Mickey, None; M. Amin, Horizon, 6, Lilly, 6; J. Potter, None; J. Schmukler, None; J. Sundhar, Abbvie, 6, Amgen, 6, Sanofi, 6, novartis, 6, pfizer, 6, medac, 6; J. Sheingold, None; D. Horowitz, None; H. Gulko, None; R. Quinet, None; S. Dhulipala, None; R. Patel, None; C. Keshavamurthy, None; G. Carvajal Bedoya, None; R. Dunn, None; B. Kumar, None; A. Lenert, None; H. Zembrzuska, None; M. Gebre, None; P. Lenert, None; A. Anandarjah, None; A. Yang, None; L. Grinnell-Merrick, Abbvie, 2, 6, Amgen, 2, 6, Novartis, 2, 6, Sanofie/Regeneron, 2, 6, Janssen, 2, 6, UCB, 2, Avion, 2, 6, Pfizzer, 2, Celegene, 2, 6, Novartis, 12, As of April 26, 2021 I am a full time employee of Novartis, I continue to work per diem at the University of Rochester Dept of Allergy, Immunology and Rheumatology; S. Goldsmith, None; J. Zelie, None; L. Wise, None; N. Zagelbaum Ward, None; J. Kaine, Sanofi-Genzyme, 3, 7.

To cite this abstract in AMA style:

Solomon D, Pincus T, Shadick N, Stratton J, Ellrodt J, Santacroce L, Katz J, Smolen J, Chatpar P, Mundell B, Stocks M, Downey C, Torralba K, White D, Baudek M, Szlembarski S, Barnhart S, Bilal J, Lee D, Redford A, Buchfuhrer J, Kramer H, Kwoh C, Villatoro-Villar M, Patnaik A, Guzman E, Trachtman R, Tesser J, Music D, Mickey L, Amin M, Potter J, Schmukler J, Sundhar J, Sheingold J, Horowitz D, Gulko H, Quinet R, Dhulipala S, Patel R, Keshavamurthy C, Carvajal Bedoya G, Dunn R, Kumar B, Lenert A, Zembrzuska H, Gebre M, Lenert P, Anandarjah A, Yang A, Grinnell-Merrick L, Goldsmith S, Zelie J, Wise L, Zagelbaum Ward N, Kaine J. Implementing Treat to Target (TTT) for Rheumatoid Arthritis (RA) Through a Virtual Learning Collaborative (LC) Program During COVID [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/implementing-treat-to-target-ttt-for-rheumatoid-arthritis-ra-through-a-virtual-learning-collaborative-lc-program-during-covid/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/implementing-treat-to-target-ttt-for-rheumatoid-arthritis-ra-through-a-virtual-learning-collaborative-lc-program-during-covid/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology